Medigene participates at four national and international conferences in January 2017

Untersuchung in einem Forschungslabor (Symbolbild). © Catalin Rusnac / iStock / Getty Images Plus / Getty Images http://www.gettyimages.de

Medigene AG / Medigene participates at four national and international conferences in January 2017 . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Martinsried/Munich, 16 December 2016. Medigene AG (FSE: MDG1, Prime Standard) announces its participation at four upcoming scientific and investor conferences:

Ringberg Conference 2017

Date: 03 January 2017
Location: Schloss Ringberg, Tegernsee, Germany
Dr. Markus Dangl, Senior Vice President Research & Pre-Clinical Development, will give a presentation on the topic: "TCRs and neoantigens: The perfect solution for personalized cancer immunotherapy?"

Oddo Forum

Date: 05 - 06 January 2017
Location: Lyon, France

J.P. Morgan Healthcare Conference

Date: 09 - 12 January 2017
Location: San Francisco, USA

Phacilitate, Cell & Gene World 2017

Date: 17 - 20 January 2017
            Location: Miami, USA
            Medigene's Senior Vice President Medical Affairs & CMO, Dr. Kai Pinkernell, will present on 18 January 2017 a case study in the session: "Optimizing preclinical data packages for efficient cell & gene therapy clinical translation"

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.

For more information, please visit www.medigene.com

ARIVA.DE Börsen-Geflüster

Kurse

Medigene

1,485 €

-2,30%

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene^®is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

Press release English PDF

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire

--- End of Message ---

Medigene AG
Lochhamer Strasse 11 Martinsried / München Germany

WKN: A1X3W0;ISIN: DE000A1X3W00;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

Mehr Nachrichten zur Medigene Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.